Physician profile
Paul E Diehl
NPI 1336215607
$1,863.71
in general payments reported to CMS, 2019-2025
21 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $91.22 · 2021: $20.34 · 2022: $63.54 · 2023: $329 · 2024: $635 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $567.36 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $312.48 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $161.42 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $159.58 | 2023-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $101.09 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $70.64 | 2019 | |
| Novo Nordisk INC | $69.80 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $49.81 | 2022-2024 | |
| Pfizer INC. | $48.39 | 2023 | |
| Abbott Laboratories | $47.67 | 2022-2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $31.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.59 | 2019 | |
| Almatica Pharma LLC | $31.46 | 2024-2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $28.71 | 2019-2020 | |
| Tolmar, INC. | $23.68 | 2025 | Jatenzo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $23.44 | 2020 | |
| Medtronic Vascular, INC. | $22.96 | 2020 | |
| Avanir Pharmaceuticals, INC. | $22.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.57 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.34 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Diehl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.